27 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
30 Apr 2024 Date | | - Cons. EPS | - EPS |
30 Nov 2023 Date | | - Cons. EPS | 0.03 EPS |
29 Nov 2023 Date | | - Cons. EPS | - EPS |
31 Oct 2016 Date | | - Cons. EPS | - EPS |
27 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
30 Apr 2024 Date | | - Cons. EPS | - EPS |
30 Nov 2023 Date | | - Cons. EPS | 0.03 EPS |
29 Nov 2023 Date | | - Cons. EPS | - EPS |
31 Oct 2016 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Mr. Daniel Carcillo CEO | OTC PINK Exchange | CA95081C1059 ISIN |
US Country | 7 Employees | - Last Dividend | 10 May 2021 Last Split | - IPO Date |
Wesana Health Holdings Inc., based in Chicago, Illinois, is a company currently not engaged in significant operations. Previously, the company focused on developing evidence-based formulations and protocols aimed at helping patients overcome a variety of neurological, psychological, and mental health issues stemming from trauma. However, the description indicates a pivot away from these activities, leaving the company's current operational status and future direction open-ended.
Previously, Wesana Health was involved in the development of several key offerings aimed at addressing trauma-related ailments: